The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans: A randomized controlled trial

Clinical Endocrinology

Volumn 79, Issue 3, 2013, Pages 356-363

  Choi, Kyung Mook ^a   Han, Kyung Ah ^b   Ahn, Hee Jung ^c   Lee, So Young ^a   Hwang, Soon Young ^a   Kim, Baek Hui ^a   Hong, Ho Cheol ^a   Choi, Hae Yoon ^a   Yang, Sae Jeong ^a   Yoo, Hye Jin ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Min, Kyung Wan ^a  

^a Korea University College of Medicine   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c Eulji General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FETUIN A; GLUCOSE; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER FUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84880825239     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12076     Document Type: Article

References (31)

1. Fontana, L., &, Klein, S., (2007) Aging, adiposity, and calorie restriction. The Journal of the American Medical Association, 297, 986-994.
2. Colman, R.J., Anderson, R.M., Johnson, S.C., et al,. (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 325, 201-204.
3. Bryson, J.M., King, S.E., Burns, C.M., et al,. (1996) Changes in glucose and lipid metabolism following weight loss produced by a very low calorie diet in obese subjects. International Journal of Obesity and Related Metabolic Disorders, 20, 338-345.
4. Srinivas, P.R., Wagner, A.S., Reddy, L.V., et al,. (1993) Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Molecular Endocrinology, 7, 1445-1455.
5. Mathews, S.T., Singh, G.P., Ranalletta, M., et al,. (2002) Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes, 51, 2450-2458.
6. Stefan, N., Hennige, A.M., Staiger, H., et al,. (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care, 29, 853-857.
7. Ix, J.H., Shlipak, M.G., Brandenburg, V.M., et al,. (2006) Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 113, 1760-1767.
8. Fiore, C.E., Celotta, G., Politi, G.G., et al,. (2007) Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis, 195, 110-115.
9. Weikert, C., Stefan, N., Schulze, M.B., et al,. (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation, 118, 2555-2562.
10. Ix, J.H., Wassel, C.L., Kanaya, A.M., et al,. (2008) Fetuin-A and incident diabetes mellitus in older persons. The Journal of the American Medical Association, 300, 182-188.
11. WHO (2000) The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia Pty Limit, Sydney, Australia.
12. Oh, S.W., (2011) Obesity and metabolic syndrome in Korea. Diabetes and Metabolism Journal, 35, 561-566.
13. Kumahara, H., Schutz, Y., Ayabe, M., et al,. (2004) The use of uniaxial accelerometry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry. British Journal of Nutrition, 91, 235-243.
14. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al,. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
15. Celermajer, D.S., Sorensen, K.E., Gooch, V.M., et al,. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340, 1111-1115.
16. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al,. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313-1321.
17. Vionnet, N., Hani, E.H., Dupont, S., et al,. (2000) Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. American Journal of Human Genetics, 67, 1470-1480.
18. Kissebah, A.H., Sonnenberg, G.E., Myklebust, J., et al,. (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 97, 14478-14483.
19. Lin, X., Braymer, H.D., Bray, G.A., et al,. (1998) Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sciences, 63, 145-153.
20. Mori, K., Emoto, M., Araki, T., et al,. (2008) Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism, 57, 1248-1252.
21. Haukeland, J.W., Dahl, T.B., Yndestad, A., et al,. (2012) Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. European Journal of Endocrinology, 166, 503-510.
22. Reinehr, T., &, Roth, C.L., (2008) Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. Journal of Clinical Endocrinology and Metabolism, 93, 4479-4485.
23. Brix, J.M., Stingl, H., Hollerl, F., et al,. (2010) Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. Journal of Clinical Endocrinology and Metabolism, 95, 4877-4881.
24. Bluher, M., Rudich, A., Kloting, N., et al,. (2012) Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care, 35, 342-349.
25. Hennige, A.M., Staiger, H., Wicke, C., et al,. (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One, 3, e1765.
26. Stefan, N., Fritsche, A., Weikert, C., et al,. (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 57, 2762-2767.
27. Sniderman, A., Couture, P., &, de Graaf, J., (2010) Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nature Reviews. Endocrinology, 6, 335-346.
28. Schinke, T., Amendt, C., Trindl, A., et al,. (1996) The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. Journal of Biological Chemistry, 271, 20789-20796.
29. Ketteler, M., Bongartz, P., Westenfeld, R., et al,. (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet, 361, 827-833.
30. Mori, K., Emoto, M., Araki, T., et al,. (2007) Association of serum fetuin-A with carotid arterial stiffness. Clinical Endocrinology (Oxford), 66, 246-250.
31. Ciaccio, M., Bivona, G., Di Sciacca, R., et al,. (2008) Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease (ESRD): effect of a single session haemodialysis. Clinical Chemistry and Laboratory Medicine, 46, 212-214. Development